Equine veterinary journal · 2025
Chronic hepatitis in horses with persistent equine hepacivirus infection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jager Mason C, Luethy Daniela, Shallop Samantha, Cathcart Jessica, Divers Thomas J, Tan Jean-Yin, Beasley Erin McConachie, Johnson Philip, Leduc Laurence, Smith Claire, Jamieson Camilla Anne, Magdesian K Gary, Van de Walle Gerlinde R, Tomlinson Joy E
Аннотация
BACKGROUND: Equine hepacivirus (EqHV) is closely related to hepatitis C virus (HCV), which causes persistent infection and chronic hepatitis in people. Information on persistent EqHV infection and hepatitis is limited.
OBJECTIVES: To report 19 cases of chronic hepatitis and persistent EqHV infection.
STUDY DESIGN: Mixed retrospective and prospective case series.
METHODS: Inclusion criteria were: (1) chronic hepatitis, defined as persistently increased serum liver biomarkers, increased serum liver biomarkers accompanied by histopathological evidence of chronicity, for example, fibrosis, or both; (2) positive serum or liver EqHV RT-qPCR; and (3) available liver histopathology. Horses were excluded if they became serum EqHV RT-qPCR undetectable, died, or were euthanised within 6 months of EqHV detection. Liver biopsies were independently reviewed.
RESULTS: Twenty-nine horses met inclusion criteria. Ten were subsequently excluded (two cleared EqHV, 8 died within 6 months). For the remaining 19 horses, the median duration of documented hepatitis was 18.4 (range, 5.2-120) months and documented EqHV viremia was 14.8 (range, 6.9-55.6) months. Histopathological findings mirrored those seen in humans with chronic HCV including fibrosis, lymphocytic infiltrate, lymphoid aggregates, and individual hepatocyte necrosis. One horse was diagnosed with bacterial cholangiohepatitis, and the remainder had no definitive etiologic diagnosis. Bacterial infection, equine parvovirus-hepatitis infection, and equine multinodular pulmonary fibrosis were frequent comorbidities.
MAIN LIMITATIONS: A direct causal link between EqHV viremia and hepatitis cannot be made from these data.
CONCLUSIONS: Some horses with persistent EqHV infection develop chronic hepatitis and liver failure, with clinical and histopathological findings resembling HCV in humans.
OBJECTIVES: To report 19 cases of chronic hepatitis and persistent EqHV infection.
STUDY DESIGN: Mixed retrospective and prospective case series.
METHODS: Inclusion criteria were: (1) chronic hepatitis, defined as persistently increased serum liver biomarkers, increased serum liver biomarkers accompanied by histopathological evidence of chronicity, for example, fibrosis, or both; (2) positive serum or liver EqHV RT-qPCR; and (3) available liver histopathology. Horses were excluded if they became serum EqHV RT-qPCR undetectable, died, or were euthanised within 6 months of EqHV detection. Liver biopsies were independently reviewed.
RESULTS: Twenty-nine horses met inclusion criteria. Ten were subsequently excluded (two cleared EqHV, 8 died within 6 months). For the remaining 19 horses, the median duration of documented hepatitis was 18.4 (range, 5.2-120) months and documented EqHV viremia was 14.8 (range, 6.9-55.6) months. Histopathological findings mirrored those seen in humans with chronic HCV including fibrosis, lymphocytic infiltrate, lymphoid aggregates, and individual hepatocyte necrosis. One horse was diagnosed with bacterial cholangiohepatitis, and the remainder had no definitive etiologic diagnosis. Bacterial infection, equine parvovirus-hepatitis infection, and equine multinodular pulmonary fibrosis were frequent comorbidities.
MAIN LIMITATIONS: A direct causal link between EqHV viremia and hepatitis cannot be made from these data.
CONCLUSIONS: Some horses with persistent EqHV infection develop chronic hepatitis and liver failure, with clinical and histopathological findings resembling HCV in humans.